Tilray Brands Inc. has achieved a groundbreaking regulatory milestone in Italy, securing the first-ever authorization from the Italian Ministry of Health to distribute medical cannabis flower for therapeutic use. This approval allows Tilray Medical, a division of Tilray Brands, to introduce three new varieties of medical cannabis in Italy: Tilray THC 25%, Tilray THC 18%, and Tilray THC 9% / CBD 9%. As the first company in Italy to receive such authorization, Tilray continues to expand its leadership in the European medical cannabis market, which includes operations in Germany, Portugal, Poland, and the United Kingdom. This development represents a significant step in enhancing patient access to high-quality, EU-GMP certified cannabinoid-based therapies across Italy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.